Green Synthesis of Size-Controlled <i>in Vivo</i> Biocompatible Immunoglobulin-Based Nanoparticles by a Swift Thermal Formation

Lunin, A. V.; Korenkov, E.S.; Mochalova, Elizaveta N.; Nikitin, Maxim P.

doi:10.1021/acssuschemeng.1c03409

Cited by 13 publications

(5 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several transcytosis-based strategies resulted in excellent tumor specificity but were not included in the analysis because “non-targeted” nanoparticles are not available, for example, for nanoparticles made of the targeting protein itself [ 126 ]. These also include transferrin nanoparticles [ 127 ], albumin nanoparticles [ 128 ], or albumin nanoparticles modified with transferrin [ 122 ].…”

Section: Resultsmentioning

confidence: 99%

Systematic Review of Cancer Targeting by Nanoparticles Revealed a Global Association between Accumulation in Tumors and Spleen

Drozdov

Никитин

Rozenberg

2021

IJMS

View full text Add to dashboard Cite

Active targeting of nanoparticles toward tumors is one of the most rapidly developing topics in nanomedicine. Typically, this strategy involves the addition of cancer-targeting biomolecules to nanoparticles, and studies on this topic have mainly focused on the localization of such formulations in tumors. Here, the analysis of the factors determining efficient nanoparticle targeting and therapy, various parameters such as types of targeting molecules, nanoparticle type, size, zeta potential, dose, and the circulation time are given. In addition, the important aspects such as how active targeting of nanoparticles alters biodistribution and how non-specific organ uptake influences tumor accumulation of the targeted nanoformulations are discussed. The analysis reveals that an increase in tumor accumulation of targeted nanoparticles is accompanied by a decrease in their uptake by the spleen. There is no association between targeting-induced changes of nanoparticle concentrations in tumors and other organs. The correlation between uptake in tumors and depletion in the spleen is significant for mice with intact immune systems in contrast to nude mice. Noticeably, modulation of splenic and tumor accumulation depends on the targeting molecules and nanoparticle type. The median survival increases with the targeting-induced nanoparticle accumulation in tumors; moreover, combinatorial targeting of nanoparticle drugs demonstrates higher treatment efficiencies. Results of the comprehensive analysis show optimal strategies to enhance the efficiency of actively targeted nanoparticle-based medicines.

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic Review of Cancer Targeting by Nanoparticles Revealed a Global Association between Accumulation in Tumors and Spleen

Drozdov

Никитин

Rozenberg

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…That causes rapid plasma clearance of the nanocarriers leading to short nanoparticle plasma half-life [102]. Therefore, it is necessary to study in detail the issues related to the factors that affect blood circulation [8,103], as well as elimination [104,105] of nanoparticles for successful applications of in vivo magnetofection, search for new hybrid delivering nanomaterials [106][107][108][109] or implementation of more efficient biochemical binding and targeting techniques [110][111][112][113][114][115][116]. However, we believe that the magnetofection technique can become a solid option for in vivo targeting combined with improved efficacy of gene delivery, potentially in combination with other physical techniques (electroporation, sonoporation) if appropriate magnetic fields can be generated and if an ideal coating of magnetic particles is found.…”

Section: Discussionmentioning

confidence: 99%

Magnetofection In Vivo by Nanomagnetic Carriers Systemically Administered into the Bloodstream

2021

Self Cite

View full text Add to dashboard Cite

Nanoparticle-based technologies are rapidly expanding into many areas of biomedicine and molecular science. The unique ability of magnetic nanoparticles to respond to the magnetic field makes them especially attractive for a number of in vivo applications including magnetofection. The magnetofection principle consists of the accumulation and retention of magnetic nanoparticles carrying nucleic acids in the area of magnetic field application. The method is highly promising as a clinically efficient tool for gene delivery in vivo. However, the data on in vivo magnetofection are often only descriptive or poorly studied, insufficiently systematized, and sometimes even contradictory. Therefore, the aim of the review was to systematize and analyze the data that influence the in vivo magnetofection processes after the systemic injection of magnetic nanostructures. The main emphasis is placed on the structure and coating of the nanomagnetic vectors. The present problems and future trends of the method development are also considered.

show abstract

“…These nanoparticles are biocompatible and capable of encapsulating other substances, such as nanosized magnetite. Using this method, nanoparticles with various portions of trastuzumab (from 10 to 100%) were obtained [ 121 ]. Imaging flow cytometry assay showed that even NPs with 10% of trastuzumab specifically bind SKBR-3 cells overexpressing receptor HER2 [ 121 ].…”

Section: Protein-based Targeting Self-assembling Nanoparticles For Bi...mentioning

confidence: 99%

Genetically Encoded Self-Assembling Protein Nanoparticles for the Targeted Delivery In Vitro and In Vivo

et al. 2023

Self Cite

View full text Add to dashboard Cite

Targeted nanoparticles of different origins are considered as new-generation diagnostic and therapeutic tools. However, there are no targeted drug formulations within the composition of nanoparticles approved by the FDA for use in the clinic, which is associated with the insufficient effectiveness of the developed candidates, the difficulties of their biotechnological production, and inadequate batch-to-batch reproducibility. Targeted protein self-assembling nanoparticles circumvent this problem since proteins are encoded in DNA and the final protein product is produced in only one possible way. We believe that the combination of the endless biomedical potential of protein carriers as nanoparticles and the standardized protein purification protocols will make significant progress in “magic bullet” creation possible, bringing modern biomedicine to a new level. In this review, we are focused on the currently existing platforms for targeted self-assembling protein nanoparticles based on transferrin, lactoferrin, casein, lumazine synthase, albumin, ferritin, and encapsulin proteins, as well as on proteins from magnetosomes and virus-like particles. The applications of these self-assembling proteins for targeted delivery in vitro and in vivo are thoroughly discussed, including bioimaging applications and different therapeutic approaches, such as chemotherapy, gene delivery, and photodynamic and photothermal therapy. A critical assessment of these protein platforms’ efficacy in biomedicine is provided and possible problems associated with their further development are described.

show abstract

Green Synthesis of Size-Controlled in Vivo Biocompatible Immunoglobulin-Based Nanoparticles by a Swift Thermal Formation

Cited by 13 publications

References 52 publications

Systematic Review of Cancer Targeting by Nanoparticles Revealed a Global Association between Accumulation in Tumors and Spleen

Systematic Review of Cancer Targeting by Nanoparticles Revealed a Global Association between Accumulation in Tumors and Spleen

Magnetofection In Vivo by Nanomagnetic Carriers Systemically Administered into the Bloodstream

Genetically Encoded Self-Assembling Protein Nanoparticles for the Targeted Delivery In Vitro and In Vivo

Contact Info

Product

Resources

About